These results further confirmed that the responsiveness of HCC to anti-PD-1 therapy was associated with the status of TAMs and CD8+ T cells, suggesting that reprogramming of TAMs to enhance CD8+ T cell function might improve the sensitivity of HCC to anti-PD-1 antibody. The gene discussed is CD8A; the disease is hepatocellular carcinoma.